TCM
INO icon

Tanaka Capital Management’s Inovio Pharmaceuticals INO Stock Holding History

Tanaka Capital Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-7,318
Closed -$688K – 52
2017
Q2 		$688K Sell
7,318
-759
-9% -$64.9K 1.58% 22
2017
Q1 		$642K Buy
+8,077
New +$644K 1.42% 24

Other funds holding INO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Tanaka Capital Management's INO Position: Q3 2017 in Review

Tanaka Capital Management sold out of Inovio Pharmaceuticals (INO) in Q3 2017, closing a stake of 7,318 shares — an estimated $688K sold.

Tanaka Capital Management first reported a position in INO in Q1 2017 and held it in 2 quarters. The position peaked at $688K in Q2 2017. 125 funds tracked by Wall St. Rank hold INO as of Q3 2017.

  • Tanaka Capital Management reported no remaining Inovio Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Tanaka Capital Management sold 7,318 Inovio Pharmaceuticals shares in Q3 2017, an estimated $688K.
  • Tanaka Capital Management first reported a position in Inovio Pharmaceuticals in Q1 2017 and held it in 2 quarters.
  • Tanaka Capital Management's Inovio Pharmaceuticals position peaked at $688K in Q2 2017.
  • 125 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2017.

Based on Tanaka Capital Management's 13F filing for Q3 2017, filed 16 Nov 2017.